Finacea®
(azelaic acid)
Foam, 15%

Meet the
BUSY EXECUTIVE

Actor portrayal.

What can treatment with Finacea® Foam do for her moderate rosacea?

Indication

Finacea® (azelaic acid) Foam, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

Important Safety Information

Warnings and Precautions

Skin Reactions: There have been isolated reports of hypopigmentation after use of azelaic acid. Because azelaic acid has not been well studied in patients with dark complexion, monitor these patients for early signs of hypopigmentation.

Eye and Mucous Membranes Irritation: Azelaic acid has been reported to cause irritation of the eyes. Avoid contact with the eyes, mouth, and other mucous membranes. If Finacea® Foam does come in contact with the eyes, wash the eyes with large amounts of water and consult a healthcare professional if eye irritation persists.

Not actual size.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

NDC 50222-303-50

Finacea® (azelaic acid) Foam, 15%

Meet SHELLY

Actor portrayal.

"I wonder if there's something out there that can help treat my moderate rosacea."

- High-level executive with a stressful job
- Has daily interactions with her coworkers
- Stress has led to a flare-up of moderate papulopustular rosacea
- She wants to know if her dermatologist has a treatment that will work for her

PROVEN EFFICACY[1] for patients like Shelly

Finacea® (azelaic acid) Foam, 15%

Reduction in inflammatory lesion count[1-3]



Significant reduction in the mean number of inflammatory lesions with Finacea® Foam vs foam vehicle‡ at 12 weeks.[1]

IGA§ success rates[1]



2 TRIALS | **1362** PATIENTS

Results demonstrated in 2 multicenter, randomized, double-blind, vehicle-controlled, 12-week clinical trials involving a total of 1362 patients (active N=681; vehicle N=681).

Finacea® Foam or its vehicle were to be applied twice daily for 12 weeks. Success was defined as a score of "Clear" or "Minimal" with at least a 2-step reduction from baseline on a 5-point IGA.§

In clinical studies, the most frequently observed adverse reactions in ≥0.5% of subjects treated with Finacea® Foam included local site pain (6.2%), pruritus (2.5%), dryness (0.7%), and erythema (0.7%).

*End of trial.
†*P*-value is calculated from 2-sided t test.
‡Foam vehicle contained the same exact hydrophilic foam minus azelaic acid.[1]
§Investigator's Global Assessment.

Important Safety Information (cont'd)

Warnings and Precautions

Flammability: The propellant in Finacea® Foam is flammable. Instruct the patient to avoid fire, flame, and smoking during and immediately following application. Do not puncture and/or incinerate the containers. Do not expose containers to heat and/or store at temperatures above 120°F (49°C).

For Topical Use Only

Finacea® Foam is not for oral, ophthalmic, or intravaginal use.

Avoid the use of occlusive dressings or wrappings at the application site. Avoid use of alcoholic cleansers, tinctures and astringents, abrasives, and peeling agents.

Patients should be reassessed if no improvement is observed upon completing 12 weeks of therapy.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

ACCESS

to Finacea® Foam through LEO Pharma® CONNECT

Finacea®
(azelaic acid)
Foam, 15%

Most eligible commercially insured patients may pay as little as

$20 per prescription at any pharmacy*

*Certain restrictions apply. This card may reduce out-of-pocket expenses. Patient must be 18 years of age or older to use this card. If patient is under 18, a legal guardian over 18 years of age may access this program on your behalf where permitted by, and consistent with, additional restrictions imposed by law (and subject to any additional age restrictions that relate to each product). Patients are not eligible if they are enrolled or they participate in any state or federally funded healthcare program (eg, Medicare, Medicaid, etc). For eligibility requirements and restrictions, visit leopharmaconnect.com or call 1-877-678-7494.

References: 1. Finacea® Foam [prescribing information]. LEO Pharma Inc. **2.** Draelos ZD, Elewski BE, Harper JC, et al. A randomized, phase 3, double-blind, vehicle-controlled clinical trial to evaluate the safety and efficacy of 12 weeks of twice-daily azelaic acid foam, 15% in papulopustular rosacea. Poster presented at: 35th Anniversary Fall Clinical Dermatology Conference; Las Vegas, Nevada; October 20-23, 2016. **3.** Draelos ZD, Elewski B, Staedler G, et al. Azelaic acid foam 15% in the treatment of papulopustular rosacea. A randomized, double-blind, vehicle controlled study. *Cutis*. 2013;92(1):306-317.

Important Safety Information (cont'd)

Most Common Adverse Reactions

In clinical studies, the most frequently observed adverse reactions in ≥ 0.5% of subjects treated with Finacea® Foam included local site pain (6.2%), pruritus (2.5%), dryness (0.7%), and erythema (0.7%).

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).

You may also report side effects to LEO Pharma Inc. at 1-877-494-4536, option 1, or email to usdrugsafety@leo-pharma.com.

Please see additional Important Safety Information throughout and accompanying full Prescribing Information.

NDC 50222-303-50